Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells

• Published in: Acta pharmacologica Sinica Vol. 25; no. 1; pp. 61 - 67
• Main Authors: Zhang, Min, Zhang, Xin, Bai, Chun-Xue, Chen, Jie, Wei, Min-Q
• Format: Journal Article
• Language: English
• Published: United States 2004
• Subjects: A549细胞; Adenocarcinoma - pathology; Cell Division - drug effects; Cisplatin - pharmacology; Humans; Lung Neoplasms - pathology; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; RNA Interference; RNA, Double-Stranded - genetics; RNA, Double-Stranded - pharmacology; RNA, Small Interfering - genetics; RNA, Small Interfering - pharmacology; RNA干扰技术; Transfection; Tumor Cells, Cultured; 表皮生长因子受体; 非小细胞肺癌
• ISSN: 1671-4083; 1745-7254

AIM: To investigate the biological features of A549 cells in which epidermal growth factor (EGF) receptors expression were suppressed by RNA interference (RNAi). METHODS: A549 cells were transfected using short small interfering RNAs (siRNAs) formulated with Lipofectamine 2000. The EGF receptor numbers were determined by Western blotting and flowcytometry. The antiproliferative effects of sequence specific double stranded RNA (dsRNA) were assessed using cell count, colony assay and scratch assay. The chemosensitivity of transfected cells to cisplatin was measured by MTT. RESULTS: Sequence specific dsRNA-EGFR down-regulated EGF receptor expression dramatically. Compared with the control group, dsRNA-EGFR reduced the cell number by 85.0 %, decreased the colonies by 63.3 %, inhibited the migration by 87.2 %, and increased the sensitivity of A549 to cisplatin by four-fold. CONCLUSION: Sequence specific dsRNA-EGFR were capable of suppressing EGF receptor expression, hence significantly inhibiting cellular proliferation and motility, and enhancing chemosensitivity of A549 cells to cisplatin. The successful application of dsRNA-EGFR for inhibition of proliferation in EGF receptor overexpressing cells can help extend the list of available therapeutic modalities in the treatment of non-small-cell lung carcinoma (NSCLC).